SCHEMBL2363101

SCHEMBL2363101

CCC(OCCC(C)C)Oc1ccc(C(=O)CC(=O)c2ccc(C(=O)OC)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RAB9A P51151 4/20 0.42
NPC1 O15118 2/20 0.42
TSHR P16473 2/20 0.42
GAA P10253 1/20 0.42
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MAPK1 P28482 3/20 0.41
HSD17B10 Q99714 3/20 0.40
ALDH1A1 P00352 2/20 0.40
THRB P10828 1/20 0.40
PKM P14618 1/20 0.40
STS P08842 1/20 0.39
STAT3 P40763 1/20 0.38
HPGD P15428 1/20 0.38
LMNA P02545 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16330960 0.92 SMN1; SMN2 (0.44) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL12243267 0.80 MAPT (0.66) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL7262172 0.80 CA1 (0.58) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL2363449 0.77 MAPT (0.64) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL2363105 0.75 MAPT (0.57) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL7256618 0.74 KMT2A (0.53) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL12948471 0.74 MAPT (0.51) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL12694298 0.74 MAPT (0.74) MAPTSMN1; SMN2RAB9ANPC1TSHR
SCHEMBL28827921 0.72 SMN1; SMN2 (0.61) MAPTSMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL4686240 0.72 SMN1; SMN2 (0.61) MAPTSMN1; SMN2MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921309-B2 Lipopeptide compounds and their use UNIQUEST PTY LIMITED (AU) 2014-12-30 US disclosed
EP-2350119-B1 LIPOPEPTIDE COMPOUNDS AND THEIR USE UNIQUEST PTY LTD (AU) 2014-10-29 EP disclosed
US-20110224129-A1 Lipopeptide Compounds and Their Use MERLION PHARMACEUTICALS PTE LTD (SG) 2011-09-15 US disclosed
EP-2350119-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE Merlion Pharmaceuticals Pte Ltd. (SG) 2011-08-03 EP disclosed
WO-2010062264-A1 LIPOPEPTIDE COMPOUNDS AND THEIR USE MERLION PHARMACEUTICALS PTE LTD (SG) 2010-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224129-A1 Lipopeptide Compounds and Their Use VIP, LTA, CLPTM1 MAPT 4432/4885SMN1; SMN2 4169/4885MEN1 2415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.